ANI Pharmaceuticals, Inc.
NASDAQ:ANIPDrug Manufacturers - Specialty & Generic
-$1.42 today
- Market cap
- $1.62B
- Beta
- 0.44
- P/E (TTM)
- 18.5
- EPS (TTM)
- $4.29
Volume 0.29M
Average 0.35M
ANIP Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
ANI Pharmaceuticals, Inc.NASDAQ: ANIP
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables dips below year-ago levels
Q1 FY2026 accounts payables of $5.36M fell 3.4% year over year, behind the +372.2% change in trailing-twelve-month accounts payables. Over 3 fiscal years it compounded at +44.4% a year.
Context
- Accounts payables amounted to 1.7% of revenue in FY2025, up 1.6 pp from a year earlier.
- Accounts payables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -3.4% toward the trailing-twelve-month pace of +372.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 15.16M USD
- Year-over-year change
- +3064.1%
- 4-year CAGR
- +10.5%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.16M | +3064.1% |
| FY2024 | 2024-12-31 | 479K | -93.7% |
| FY2023 | 2023-12-31 | 7.55M | +49.9% |
| FY2022 | 2022-12-31 | 5.04M | -50.4% |
| FY2021 | 2021-12-31 | 10.17M | — |
Accounts Payables vs competitors
How ANIP compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +372.2% is the highest of 8, against a peer median of -121.6%.
- Accounts payables amounts to 1.6% of revenue for ANIP, versus a peer median of 1.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | ₹7.14B INR | — | — | 2.2% | |
| LTM Jun 2026 | $366.12M USD | -275.5% | +1.0% | 3.4% | |
| LTM Jun 2026 | $33.2M USD | +115.8% | — | 0.2% | |
| LTM Jun 2026 | $30.41M USD | -34.0% | -42.1% | 1.0% | |
| LTM Mar 2026 | $14.97M USD | +372.2% | +44.4% | 1.6% | |
| LTM Mar 2026 | $12.56M USD | -121.6% | +83.7% | 1.7% | |
| LTM Mar 2026 | $11.03M USD | -313.0% | — | 1.4% | |
| LTM Mar 2026 | $9.87M USD | -72.1% | — | 3.7% | |
| LTM Mar 2026 | $2.23M USD | -153.0% | +118.5% | 0.7% | |
| LTM Mar 2026 | $734K USD | — | — | 0.5% | |
| LTM Jun 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding ANIP) | — | -121.6% | +42.3% | 1.2% | |
Competitors are the stored peer set for ANIP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (42.6M) | (47.9M) | 18.78M | (18.52M) | 78.34M |
| Depreciation & Amortization | 47.25M | 59.65M | 59.79M | 67.73M | 91.42M |
| Deferred Income Tax | (16.75M) | (15.25M) | (11.74M) | (21.91M) | 14.24M |
| Stock-Based Compensation | 10.49M | 14.6M | 20.65M | 29.34M | 37.93M |
| Change in Working Capital | (84K) | (51.3M) | 24.86M | (11.19M) | (7.12M) |
| Accounts Receivables | (5.55M) | (36.91M) | 3.36M | (21.09M) | (58.53M) |
| Inventory | 3.22M | (23.63M) | (5.84M) | (21.29M) | (5.96M) |
| Accounts Payables | 10.17M | 5.04M | 7.55M | 479K | 15.16M |
| Other Working Capital | (7.93M) | 4.2M | 19.79M | 30.71M | 42.21M |
| Other Non-Cash Items | 5.02M | 8.99M | 6.62M | 18.56M | (29.57M) |
| Operating Cash Flow | 3.32M | (31.2M) | 118.96M | 64.02M | 185.23M |
| Capital Expenditures | (23.64M) | (16.46M) | (18.51M) | (16.95M) | (34.32M) |
| Acquisitions (Net) | (84.49M) | (33K) | 0 | (401.28M) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (18.43M) | (6.83M) | (9.64M) | 12.8M | (20.49M) |
| Investing Cash Flow | (105.48M) | (15.74M) | (18.51M) | (404.72M) | (34.32M) |
| Debt Repayment | 99.02M | (3M) | (3M) | 345.22M | (10.16M) |
| Common Stock Issued | 69.58M | 0 | 80.56M | 0 | 13.6M |
| Common Stock Repurchased | (890K) | (1.96M) | (4.99M) | (10.96M) | (12.21M) |
| Dividends Paid | (190K) | (1.63M) | (1.63M) | (1.63M) | (1.16M) |
| Other Financing Activities | 2.07M | 1.46M | (3.5M) | (67.69M) | (26K) |
| Financing Cash Flow | 194.6M | (5.13M) | 67.44M | 264.95M | (9.94M) |
| Effect of Forex Changes | 0 | 0 | 0 | (470K) | (233K) |
| Net Change in Cash | 92.43M | (52.07M) | 167.89M | (76.23M) | 140.73M |
| Free Cash Flow | (20.32M) | (47.66M) | 100.45M | 47.06M | 150.9M |
ANI Pharmaceuticals, Inc.
NASDAQ:ANIP
Intrinsic Alpha fair value
Locked
Current Price
$71.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.